

2023 PDA Cell & Gene Pharmaceutical Products Conference

The Present and Future of Manufacturing & Quality of Cell-based Products

12-13 July 2023 | Tokyo, Japan

Academic Partner:

・般社団法人日本再生医療学会/大阪大学大学院工学研究科(テクノアリーナ 細胞製造コトづくり拠点) 一般社団法人再生医療イノベーションフォーラム(FIRM)/公益財団法人 京都大学 iPS 細胞研究財団

PLATINUM SPONSORS



























PDA Cell & Gene Pharmaceutical Products Conference

2023-07-12

Time	Title	Speaker
9:30	Reception	
10:00	Opening declaration	Yoji Sato (NIHS Division Head of Division Of Cell-Based Therapeutic Products)
10:15	Opening Remarks	Glenn Wright (PDA President)
11:00	Key note lecture 1 Achieving Consistent Scalable Low-cost Production of High-Quality Living Therapeutic Cells.	Sean Palecek (University of Wisconsin, Professor)
12:00	Key note lecture 2 Current Status, Issues, and Direction of regenerative medicine products in Japan	Tomonori Nakayama (MHLW Division Head of Medical Device Evaluation Division)
12:30	Lunch	<product demos=""> 12:40 - 12:55 MERCK 13:00 - 13:15 Airex</product>
13:30	Session 1 sterility	Moderator: Richard Denk (SKAN) / Yasuhito Ikematsu (OSAKA UNIV.)
13:30	Presentation 1 Efforts of the PDA Pharmaceutical Society of Japan for practical use, dissemination, and development of rapid microbial testing methods	Mitsuo Mori (Kyowa Kirin Co., Ltd.)
15:00	Coffee Break	
15:45	Presentation 2 Contamination Control Strategy and Rapid Microbiological Methods in PIC/S GMP Annex 1 and Annex 2A	Yasuhito Ikematsu (Specially Appointed Associate Professor, Graduate School of Engineering, Osaka University)
16:15	Presentation 3 Strategies and Examples for Ensuring Sterility of Cell-Processed Products	Tetsuya Karino (Sumitomo Pharma Co.,Ltd.)
17:15	Panel Discussion	
17:40-19:20	Social gathering (buffet)	

2023-07-13

tle	Speaker
eception	
ey note lecture 3 PDA Points to Consider for the Engineering and Manufacturing of Cell & Gene "ATMPs"	Richard Denk (SKAN Consultant Aseptic Processing & Containment)
ession 2 process	Moderator: Masahiro Kino-oka (Osaka Univ.)
resentation 4 The Role of Virus Filtration in Achieving Virus Safety of Cell and Gene Therapy Products	Tomoko Hongo (Asahi Kasei Medical)
resentation 5 Production and quality control of clinical-grade iPSCs and differentiated cells using an automated closed culture system.	Masayoshi Tsukahara (Research and Development Center, CiRA Foundation)
resentation 6 Introduction and Process & Quality design for Alofisel Manufacturing Facility in Japan	Seitaro Mizukami (Takeda Pharamaceutical Industry)
resentation 7 Lessons learned from clinic to commercialization for C> product	Sang Yoon (Samsung Biologics Senior Director of Quality)
anel Discussion	
Lunch	<product demos=""> 13:10 - 13:25 bioMérieux</product>
ession 3 quality	Moderator: Shingo Sakurai (Tokyo University of Science)
resentation 8 What does the ICHQ5A revision mean for your cell & gene therapy product?	Dr Edmund Ang (Senior Technical Expert, Asia Pacific, BioReliance® Contract Testing Service At Merck KGaA)
resentation 9 Regenerative Medicine Product Quality Review and Issues	Akiyoshi Kunieda (PMDA Office of Celler and Tissue-based Products)
Coffee Break	
resentation 10 PMDA's GMP/GCTP survey and risk communication activities	Kazuji Omori (PMDA Office Of Manufacturing Quality for Drugs)
resentation 11 CQA Mining: A systematic approach for identifying CQAs of cell therapy products	Yoji Sato, Ph.D. (Head, Division of Drugs/Division of Cell-Based Therapeutic Products, National Institute of Health Sciences)
anel Discussion	
vited Lecture Challenging of development for a stable process based on cell manufacturability	Masahiro Kino-oka (Professor BioProcess Systems Engineering Lab., Dept.Biotech., Grad. Sch. Eng., Osaka Univ.)
ummary & Closing remarks	Richard Denk (SKAN Consultant Aseptic Processing & Containment)
reereereereereereereereereereereereeree	sentation 4 The Role of Virus Filtration in Achieving Virus Safety of Cell and Gene Therapy Products sentation 5 Production and quality control of clinical-grade iPSCs and differentiated cells using an automated closed culture system. sentation 6 Introduction and Process & Quality design for Alofisel Manufacturing Facility in Japan sentation 7 Lessons learned from clinic to commercialization for C> product Lunch sion 3 quality sentation 8 What does the ICHQSA revision mean for your cell & gene therapy product? sentation 9 Regenerative Medicine Product Quality Review and Issues Coffee Break sentation 10 PMDA's GMP/GCTP survey and risk communication activities sentation 11 CQA Mining: A systematic approach for identifying CQAs of cell therapy products teld Lecture Challenging of development for a stable process based on cell manufacturability